Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is expanding the clinical development of its proprietary multiple sclerosis therapy candidate, LUCID-MS, following positive safety data from Phase 1 studies. The therapy, designed to target demyelination and protect or restore myelin integrity, could represent a significant shift in the treatment of multiple sclerosis (MS), a chronic neurodegenerative disease affecting millions worldwide.
According to the company, Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated. This supports advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The company believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. Current MS treatments primarily focus on modulating the immune system to reduce attacks on myelin, but LUCID-MS targets the underlying damage and repair process. This mechanism could provide new hope for patients who experience progressive disability despite existing therapies.
To strengthen operational support for the program, Quantum BioPharma is planning a partnership with Allucent, a clinical research organization, and engaging with neurological specialists. These steps are critical for efficient trial execution and regulatory navigation.
The implications of this development are substantial. Multiple sclerosis affects approximately 2.8 million people globally, and many patients face limited treatment options, especially for progressive forms of the disease. A therapy that can reverse myelin degradation could alter the disease trajectory, potentially reducing disability and improving quality of life. For the biopharmaceutical industry, LUCID-MS represents a novel therapeutic class that could open new avenues for treating other demyelinating conditions.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
For more information on Quantum BioPharma and its pipeline, visit the company’s newsroom at https://ibn.fm/QNTM. The full article detailing this announcement can be accessed at https://ibn.fm/AUhNl.
